Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.67 |
| ▸ | DPP8 | Q6V1X1 | 13/20 | 0.67 |
| ▸ | DPP9 | Q86TI2 | 13/20 | 0.67 |
| ▸ | DPP7 | Q9UHL4 | 13/20 | 0.67 |
| ▸ | FAP | Q12884 | 10/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27452954 | 0.91 | DPP4 (0.80) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL5713150 | 0.91 | DPP4 (0.80) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL5713152 | 0.91 | DPP4 (0.80) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL2182020 | 0.91 | DPP4 (0.80) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL2195630 | 0.91 | DPP4 (0.80) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7298604 | 0.91 | DPP4 (0.80) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL8501824 | 0.87 | DPP4 (0.74) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL29709280 | 0.86 | ACE (0.65) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7375090 | 0.83 | ACE (0.70) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6436643 | 0.83 | ACE (0.70) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | DPP4 525/4885DPP8 644/4885DPP9 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.